Have a personal or library account? Click to login
Organotin (IV) based Rabeprazole and Pregabalin Complexes Formation and Biocidal Investigation Cover

Organotin (IV) based Rabeprazole and Pregabalin Complexes Formation and Biocidal Investigation

Open Access
|Jun 2020

References

  1. [1] A.F. Butt, M.N. Ahmed, M.H. Bhatti, M.A. Choudhary, K. Ayub, M.N. Tahir, and T. Mahmood, “Synthesis, structural properties, DFT studies, antimicrobial activities and DNA binding interactions of two newly synthesized organotin (IV) carboxylates”, J. Mol. Struct., Vol. 1191, Pp. 291-300, 2019.10.1016/j.molstruc.2019.04.066
  2. [2] M. Sirajuddin, S. Ali, V. McKee, N. Akhtar, S. Andleeb, and A. Wadood, “Spectroscopic characterizations, structural peculiarities, molecular docking study and evaluation of biological potential of newly designed organotin (IV) carboxylates”, J. Photochem. Photobiol. B., Vol. 197, Pp. 111-116, 2019.10.1016/j.jphotobiol.2019.111516
  3. [3] A. Munir, M. Sirajuddin, M. Zubair, A. Haider, S.A. Tirmizi, S. Ali, and I. Aziz, “Synthesis, spectroscopic characterization, and biological screening of levofloxacin based organotin (IV) derivatives”, Russ. J. Gen. Chem., Vol. 87, No. 10, Pp. 2380-2390, 2017.10.1134/S1070363217100206
  4. [4] F.F. Yan, Q. Zhu, Q.L. Li, R.F. Zhang, and C.L. Ma, “Triorganotin coordination polymers based on three dicarboxylate ligands containing flexible SS bonds: synthesis, structures and in vitro anti-tumor activity”, J. Organomet. Chem., Vol. 880, Pp. 156-162, 2019.10.1016/j.jorganchem.2018.11.003
  5. [5] I. Ahmad, A. Waseem, M. Tariq, C. Macbeth, J. Bacsa, D. Venkataraman, and S. Tabassum, “Organotin (IV) derivatives of amide-based carboxylates: Synthesis, spectroscopic characterization, single crystal studies and antimicrobial, antioxidant, cytotoxic, anti-leishmanial, hemolytic, noncancerous, anticancer activities”, Inorg. Chim. Acta, Pp. 119-133, 2020.10.1016/j.ica.2020.119433
  6. [6] S. Naz, M. Sirajuddin, I. Hussain, A. Haider, A. Nadhman, A. Gul, and S. Ali, “2-Phenylbutyric acid based organotin (IV) carboxylates; synthesis, spectroscopic characterization, antibacterial action against plant pathogens and in vitro hemolysis”, J. Mol. Struct., 1203, 127378, 2020.10.1016/j.molstruc.2019.127378
  7. [7] M. Sirajuddin, V. McKee, M. Tariq, and S. Ali, “Newly designed organotin (IV) carboxylates with peptide linkage: synthesis, structural elucidation, physicochemical characterizations and pharmacological investigations”, Eur. J. med. Chem., Vol. 143, Pp. 1903-1918, 2018.10.1016/j.ejmech.2017.11.001
  8. [8] M. Sirajuddin, S. Ali, V. McKee, and A. Matin, “Synthesis, characterization and biological screenings of 5-coordinated Organotin (IV) complexes based on carboxylate ligand”, J. Mol. Struct., 127683, 2020.10.1016/j.molstruc.2020.127683
  9. [9] R. Guan, Z. Zhou, M. Zhang, H. Liu, W. Du, X. Tian, and Y. Tian, “Organotin (IV) carboxylate complexes containing polyether oxygen chains with two-photon absorption in the near infrared region and their anticancer activity”, Dyes Pigments, Vol. 158, Pp. 428-437, 2018.10.1016/j.dyepig.2018.05.072
  10. [10] C.N. Banti, S.K. Hadjikakou, T. Sismanoglu, and N. Hadjiliadis, “Anti-proliferative and antitumor activity of organotin (IV) compounds. An overview of the last decade and future perspectives”, J. Inorg. Biochem., Vol. 194, Pp. 114-152, 2019.10.1016/j.jinorgbio.2019.02.003
  11. [11] A.M. Sakho, D. Du, W. Li, S. Liu, D. Zhu, and L. Xu, “Synthesis, crystal structures, and antitumor activity of three new organotin carboxylates”, Heteroatom Chem., Vol. 21, No. 5, Pp. 304-313, 2010.10.1002/hc.20614
  12. [12] J.O. Adeyemi, D.C. Onwudiwe, A.C. Ekennia, S.N. Okafor, and E.C. Hosten, “Organotin (IV) N-butyl-N-phenyldithiocarbamate complexes: Synthesis, characterization, biological evaluation and molecular docking studies”, J. Mol. Struct., Vol. 1192, Pp. 15-26, 2019.10.1016/j.molstruc.2019.04.097
  13. [13] K.M. Fock, T.L. Ang, L.C. Bee, and E.J.D. Lee, “Proton pump inhibitors”, Clin. Pharmacokinet, Vol. 47, No. 1, Pp. 1-6, 2008.10.2165/00003088-200847010-00001
  14. [14] L.S. Welage, and R.R. Berardi, “Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases”, J. Am. Pharm. Assoc., Vol. 40, No.1, Pp. 52-62, 2000.10.1016/S1086-5802(16)31036-1
  15. [15] F. Salama, N. El-Abasawy, S.A. Razeq, M.M.F. Ismail, and M.M. Fouad, “Validation of the spectrophotometric determination of omeprazole and pantoprazole sodium via their metal chelates”, J. Pharmaceu. Biomed. Anal., Vol. 33, No. 3, Pp. 411-421, 2003.10.1016/S0731-7085(03)00233-4
  16. [16] C. Vidaillac, J. Guillon, C. Arpin, I. Forfar-Bares, B.B. Ba, J. Grellet, and C. Quentin, “Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus”, Antimicrob. Agents chemother. Vol. 51, No. 3, Pp. 831-838, 2007.10.1128/AAC.01306-05180315617101679
  17. [17] M. Tariq, M. Sirajuddin, S. Ali, N. Khalid, and N.A. Shah, “Biological evaluations and spectroscopic characterizations of 3-(4-ethoxyphenyl)-2-methylacrylate based organotin (IV) carboxylates derivatives”, Russ. J. Gen. Chem., Vol. 87, No. 11, Pp. 2690-2698, 2017.10.1134/S1070363217110263
  18. [18] M. Tariq, N. Muhammad, S. Ali, J.H. Shirazi, M.N. Tahir, and N. Khalid, “Synthesis, spectroscopic, X-ray crystal structure, biological and DNA interaction studies of organotin (IV) complexes of 2-(4-ethoxybenzylidene) butanoic acid. Spectrochim”, Acta A:, Vol. 122, Pp. 356-364, 2014.10.1016/j.saa.2013.11.06524322756
  19. [19] M. Iqbal, S. Ali, A. Haider, and N. Khalid, “Therapeutic properties of organotin complexes with reference to their structural and environmental features”, Rev. Inorg. Chem., Vol. 37, No. 2, Pp. 51-70, 2017.10.1515/revic-2016-0005
  20. [20] R. Kumar, A. Rani, S.P. Singh, K.M. Kumari, and S.S. Srivastava, “A long term study on chemical composition of rainwater at Dayalbagh, a suburban site of semiarid region”, J. Atmos. Chem., Vol. 41, No. 3, Pp. 265-279, 2002.10.1023/A:1014955715633
  21. [21] N. Rani, A. Sharma, and R. Singh, “Imidazoles as promising scaffolds for antibacterial activity: a review”, Mini Rev. Med. Chem., Vol. 13, No. 12, Pp. 1812-1835, 2013.10.2174/13895575113136660091
  22. [22] L. Zhang, X.M. Peng, G.L. Damu, R.X. Geng, and C.H. Zhou, “Comprehensive review in current developments of imidazole-based medicinal chemistry”, Med. Res. Rev., Vol. 34, No. 2, Pp. 340-437, 2014.10.1002/med.2129023740514
  23. [23] W.L. Armarego, and C.L. Chai, “Purification of laboratory chemicals”, third ed., Pergamon Press, Berlin, 2013.10.1016/B978-0-12-382161-4.00004-2
  24. [24] M.I. Choudhary, and W.J. Thomsen, “Bioassay techniques for drug development”, CRC Press. Harwood Academic Publishers, Amsterdam, The Netherlands, 2001.
  25. [25] M. Tariq, N. Muhammad, M. Sirajuddin, S. Ali, N.A. Shah, N. Khalid, and M.R. Khan, “Synthesis, spectroscopic characterization, X-ray structures, biological screenings, DNA interaction study and catalytic activity of organotin (IV) 3-(4-flourophenyl)-2-methylacrylic acid derivatives”, J. Organomet. Chem., Vol. 723, Pp. 79-89, 2013.10.1016/j.jorganchem.2012.09.011
  26. [26] S. Nazir, J. Anwar, M.A. Munawar, J.I. Qazi, S.P. Best, M. Cheah, and M. Yaseen, “Metal complexation induces antibiotic activity in S-ethyl-l-cysteine sulfoxide”, Inorg. Chim. Acta, Vol. 478, Pp. 166-175, 2018.10.1016/j.ica.2018.04.002
  27. [27] M. Calligaris, “Structure and bonding in metal sulfoxide complexes: an update”, Coord. Chem. Rev., Vol. 248, No. 3-4, Pp. 351-375, 2004.10.1016/j.ccr.2004.02.005
Language: English
Page range: 17 - 23
Published on: Jun 29, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2020 Muhammad Tariq, Ahmad Kaleem Qureshi, Muhammad Hamid, Naseem Abbas, Ajaz Hussain, Muhammad Naeem Khan, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.